DOI QR코드

DOI QR Code

Bioequivalence of LANIDIEM® Tablet 4 mg to Vaxar® Tablet 4 mg(Lacidipine 4 mg)

박사르®정 4 밀리그램(라시디핀 4 mg)에 대한 라니디엠®정 4 밀리그램의 생물학적동등성

  • Lee, Yun-Young (Department of Drug Development Service, BioCore Co., Ltd.) ;
  • Kim, Hye-Jin (Department of Drug Development Service, BioCore Co., Ltd.) ;
  • La, Sookie (Department of Drug Development Service, BioCore Co., Ltd.) ;
  • Cho, Kyung-Hee (Department of Drug Development Service, BioCore Co., Ltd.) ;
  • Jang, Moon-Sun (Department of Drug Development Service, BioCore Co., Ltd.) ;
  • Park, Young-Joon (Samil Pharm. Co., Ltd.) ;
  • Lee, Hee-Joo (Department of Drug Development Service, BioCore Co., Ltd.)
  • Received : 2010.03.05
  • Accepted : 2010.04.13
  • Published : 2010.04.20

Abstract

A bioequivalence study of LANIDIEM$^{(R)}$ tablet 4 mg (Samil. Co., Ltd.) to Vaxar$^{(R)}$ tablet 4 mg (GlaxoSmithKline Co., Ltd.) was conducted according to the guidelines of Korea Food and Drug Administration (KFDA). Forty healthy male Korean volunteers were enrolled in the study and thirty six volunteers completed the study according to the protocol. Thirty six volunteers received each medicine at the lacidipine dose of 4 mg in a $2{\times}2$ crossover study. There was one week wash-out period between the doses. Plasma concentrations of lacidipine were monitored by a high performance liquid chromatography - tandem mass spectrometry (LC-MS/MS) for over a period of 24 hours after drug administration. $AUC_t$ (the area under the plasma concentration-time curve from time zero to 24 hr) was calculated by the linear trapezoidal rule method. $C_{max}$ (maximum plasma drug concentration) and $T_{max}$ (time to reach $C_{max}$) were compiled from the plasma concentration-time data. Analysis of variance was carried out using logarithmically transformed $AUC_t$ and $C_{max}$. No significant sequence effect was found for all of the bioavailability parameters indicating that the crossover design was properly performed. The 90% confidence intervals of the $AUC_t$ ratio and the $C_{max}$ ratio for LANIDIEM$^{(R)}$/Vaxar$^{(R)}$ were log 0.8102~log 1.0417 and log 0.8493~log 1.1439, respectively. These values were within the acceptable bioequivalence intervals of log 0.80~log 1.25. Thus, our study demonstrated the bioequivalence of LANIDIEM$^{(R)}$ tablet 4 mg and Vaxar$^{(R)}$ tablet 4 mg with respect to the rate and extent of absorption.

Keywords

References

  1. P. Tcherdakoff and the Investigators of Study LAC-05-91, French large-scale study evaluating the tolerability and efficacy of lacidipine, J. Cardiovasc. Pharmacol., 25, S27-S32 (1995). https://doi.org/10.1097/00005344-199500003-00007
  2. P.L. McCormack and A. J. Wagstaff, Lacidipine: a review of its use in the management of hypertension, Drugs, 63, 2327-2356 (2003). https://doi.org/10.2165/00003495-200363210-00008
  3. L. Squassante, E. Caveggion, S. Braggio, M. Pellegatti and P. Baroldi, A study of plasma disposition kinetics of lacidipine after single oral ascending doses, J. Cardiovasc. Pharmacol., 23, S94-S97 (1994) https://doi.org/10.1097/00005344-199423005-00020
  4. L. Da Ros, L. Squassante and S. Milleri, Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteers, Clin. Pharmacokinet., 42, 99-106 (2003). https://doi.org/10.2165/00003088-200342010-00004
  5. J. Tang, R. Zhu, R. Zhao, G. Cheng and W. Peng, Ultraperformance liquid chromatography-tandem mass spectrometry for the determination of lacidipine in human plasma and its application in a pharmacokinetic study, J. Pharm. Biomed. Anal., 47, 923-928 (2008). https://doi.org/10.1016/j.jpba.2008.04.018
  6. 식품의약품안전청 고시 제 2005-31호, 생물학적동등성시험기준 (2005. 06. 07).
  7. N.V.S. Ramakrishna, K.N. Vishwottam, S. Puran, S. Manoj, M. Santosh and M. Koteshwara, Simple, sensitive and rapid liquid chromatographic/ electrospray ionization tandem mass spectrometric method for the quantification of lacidipine in human plasma, J. Mass Spectrom., 39, 824-832 (2004). https://doi.org/10.1002/jms.664
  8. ICH guideline; Validation of analytical procedures: Methodology (1996).